CORMEDIX INC. ANNOUNCES APPOINTMENT OF PHOEBE MOUNTS AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL Berkeley Heights, NJ &#x2013

CORMEDIX INC. ANNOUNCES APPOINTMENT OF PHOEBE MOUNTS AS EXECUTIVE

VICE PRESIDENT AND GENERAL COUNSEL

Berkeley Heights, NJ

Mar. 21, 2019 CorMedix Inc. (NYSE American: CRMD), a

biopharmaceutical company focused on developing and commercializing

therapeutic products for the prevention and treatment of infectious

and inflammatory disease, today announced the appointment of Dr.

Phoebe Mounts, Esq. as Executive Vice

President and General Counsel, reporting to Khoso Baluch, CEO. Dr.

Mounts, currently a partner at the law firm Morgan Lewis, will head

up the Company's legal, compliance and regulatory affairs.

She will be joining CorMedix on May 1st..

I am delighted to have Phoebe as a member of the executive

team, said Mr. Baluch. She has been a trusted legal

advisor to the Company since 2013, and has been responsible for

developing the FDA regulatory strategies for Neutrolin .

Bringing her in-house will afford CorMedix full-time access to her

critical capabilities, which I believe will greatly benefit the

Company at this stage of its development.

Dr. Mounts has been providing legal counsel to life sciences

companies for over 20 years while at Morgan Lewis. In addition to

representing pharmaceutical companies, biotechnology companies and

medical device manufacturers on FDA regulatory issues, she has

provided strategic counsel on product development issues,

collaborations, and data integrity investigations.

Prior to graduating from Georgetown University Law Center, Dr.

Mounts was on the faculty of the Johns Hopkins University School of

Public Health for 16 years, specializing in molecular biology and

infectious disease. She received her Ph.D. in molecular biology

from the University of Edinburgh in Scotland.

CorMedix Inc. is a biopharmaceutical company focused on developing

and commercializing therapeutic products for the prevention and

treatment of infectious and inflammatory diseases. The Company is

focused on developing its lead product Neutrolin ,

a novel, non-antibiotic antimicrobial solution designed to prevent

costly and dangerous bloodstream infections associated with the use

of central venous catheters, currently in Phase 3 development for

patients undergoing chronic hemodialysis. Such infections have

significant treatment costs and lead to increased morbidity and

mortality. Neutrolin has FDA Fast Track status and is designated as

a Qualified Infectious Disease Product, which provide the potential

for priority review of a marketing application by FDA and

together with taurolodine's status as a new chemical entity

allow for a total of ten years of market exclusivity in the event

of U.S. approval. Neutrolin is already marketed as a CE Marked

product in Europe and other territories. In parallel, CorMedix is

leveraging its taurolidine technology to develop a pipeline of

antimicrobial medical devices, with active programs in surgical

sutures and meshes, and topical hydrogels. The company is

also working with top-tier researchers to develop taurolidine-based

therapies for rare pediatric cancers. For more information,

visit: www.cormedix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995

that are subject to risks and uncertainties. All statements, other

than statements of historical facts, regarding management's

expectations, beliefs, goals, plans or CorMedix's prospects,

future financial position, financing plans, future revenues and

projected costs should be considered forward-looking. Readers are

cautioned that actual results may differ materially from

projections or estimates due to a variety of important factors,

including: the ability to retain and hire necessary personnel to

staff our operations appropriately; the results of our discussions

with the FDA regarding the Neutrolin development path; the

resources needed to complete the information required to submit a

new drug application for Neutrolin to the FDA; the risks and

uncertainties associated with CorMedix's ability to manage

its limited cash resources and the impact on current, planned or

future research, including the continued development of Neutrolin

and research for additional uses for taurolidine; obtaining

additional financing to support CorMedix's research and

development and clinical activities and operations; and preclinical

results are not indicative of success in clinical trials and might

not be replicated in any subsequent studies or trials. These and

other risks are described in greater detail in CorMedix's

filings with the SEC, copies of which are available free of charge

at the SEC's website at www.sec.gov or upon request from

CorMedix. CorMedix may not actually achieve the goals or plans

described in its forward-looking statements, and investors should

not place undue reliance on these statements. CorMedix assumes no

obligation and does not intend to update these forward-looking

statements, except as required by law.